Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07617805 Phase 1, Phase 2
Recruiting
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Condition
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment
42 pts
Location
China
Sponsor
Beijing Biotech
NCT06207305 Phase 1, Phase 2
Recruiting
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic App...
Condition
Metastatic Appendiceal Adenocarcinoma
Enrollment
39 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07441889 Phase 1, Phase 2
Recruiting
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Condition
Breast Cancer
Enrollment
23 pts
Location
United States
Sponsor
University of Virginia
NCT06303505 Phase 1, Phase 2
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Pa...
Condition
Ovarian Cancer
Enrollment
334 pts
Location
United States, Belgium, Germany
Sponsor
Gilead Sciences
NCT06703177 Phase 1, Phase 2
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies ...
Condition
Advanced Solid Tumors
Enrollment
876 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT06134375 Phase 1, Phase 2
Recruiting
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Condition
Triple Negative Breast Cancer
Enrollment
204 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT04707300 Phase 1, Phase 2
Recruiting
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTL...
Condition
Hematologic Malignancy
Enrollment
10 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux
NCT07480928 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pan...
Condition
Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment
42 pts
Location
China
Sponsor
Beijing Biotech
NCT04544592 Phase 1, Phase 2
Recruiting
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Condition
B-cell Acute Lymphoblastic Leukemia
Enrollment
45 pts
Location
United States
Sponsor
University of Colorado, Denver
NCT07066995 Phase 1, Phase 2
Recruiting
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Can...
Condition
Pancreatic Cancer
Enrollment
60 pts
Location
China
Sponsor
Essen Biotech
NCT05943067 Phase 1, Phase 2
Recruiting
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
Condition
Hematologic Malignancy
Enrollment
60 pts
Location
Germany
Sponsor
University Hospital Tuebingen
NCT07232602 Phase 1, Phase 2
Recruiting
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortu...
Condition
Bladder Cancer
Enrollment
55 pts
Location
United States, Chile, France
Sponsor
Merck Sharp & Dohme LLC
NCT07399769 Phase 1, Phase 2
Recruiting
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
Condition
Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
Enrollment
20 pts
Location
China
Sponsor
Shenzhen University General Ho
NCT06607770 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple L...
Condition
Lung Cancer
Enrollment
20 pts
Location
China
Sponsor
Zhou Chengzhi
NCT04146298 Phase 1, Phase 2
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic ...
Condition
Pancreatic Cancer
Enrollment
30 pts
Location
China
Sponsor
Changhai Hospital
NCT05616793 Phase 1, Phase 2
Recruiting
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retina...
Condition
LCA5
Enrollment
22 pts
Location
United States
Sponsor
Opus Genetics, Inc
NCT07653685 Phase 1, Phase 2
Recruiting
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without B...
Condition
Colorectal Cancer
Enrollment
71 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT06567015 Phase 1, Phase 2
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGF...
Condition
Non-small Cell Lung Cancer (NSCLC)
Enrollment
171 pts
Location
United States, China, France
Sponsor
Pierre Fabre Medicament
NCT03685890 Phase 1, Phase 2
Recruiting
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treat...
Condition
Melanoma
Enrollment
74 pts
Location
Netherlands, Sweden
Sponsor
Vastra Gotaland Region
NCT05826535 Phase 1, Phase 2
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Condition
Relapsed Non-Hodgkin Lymphoma
Enrollment
270 pts
Location
United States, Australia
Sponsor
Lyell Immunopharma, Inc.
NCT06379789 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX G...
Condition
Hemophilia B
Enrollment
130 pts
Location
United States, Australia, Brazil
Sponsor
Regeneron Pharmaceuticals
NCT07815678 Phase 1, Phase 2
Recruiting
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Eff...
Condition
Obesity
Enrollment
164 pts
Location
United States
Sponsor
Aconcagua Bio, Inc. a wholly o
NCT07101640 Phase 1, Phase 2
Recruiting
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infan...
Condition
Bronchopulmonary Dysplasia (BPD)
Enrollment
28 pts
Location
United States
Sponsor
Duke University
NCT05413850 Phase 1, Phase 2
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Condition
Prostate Cancer
Enrollment
82 pts
Location
United States, Belgium, Germany
Sponsor
Blue Earth Therapeutics Ltd
NCT06316427 Phase 1, Phase 2
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell ...
Condition
T-cell Acute Lymphoblastic Leukemia
Enrollment
80 pts
Location
China
Sponsor
Beijing GoBroad Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology